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Abstract
HtrA2(Omi) protease controls protein quality in mitochondria and plays a major role in apo-
ptosis. Its HtrA2S306A mutant (with the catalytic serine routinely disabled for an X-ray study
to avoid self-degradation) is a homotrimer whose subunits contain the serine protease
domain (PD) and the regulatory PDZ domain. In the inactive state, a tight interdomain inter-
face limits penetration of both PDZ-activating ligands and PD substrates into their respec-
tive target sites. We successfully crystalized HtrA2V226K/S306A, whose active counterpart
HtrA2V226K has had higher proteolytic activity, suggesting higher propensity to opening the
PD-PDZ interface than that of the wild type HtrA2. Yet, the crystal structure revealed the
HtrA2V226K/S306A architecture typical of the inactive protein. To get a consistent interpreta-
tion of crystallographic data in the light of kinetic results, we employed molecular dynamics
(MD). V325D inactivating mutant was used as a reference. Our simulations demonstrated
that upon binding of a specific peptide ligand NH2-GWTMFWV-COOH, the PDZ domains
open more dynamically in the wild type protease compared to the V226K mutant, whereas
the movement is not observed in the V325D mutant. The movement relies on a PDZ vs. PD
rotation which opens the PD-PDZ interface in a lid-like (budding flower-like in trimer) fash-
ion. The noncovalent hinges A and B are provided by two clusters of interfacing residues,
harboring V325D and V226K in the C- and N-terminal PD barrels, respectively. The opening
of the subunit interfaces progresses in a sequential manner during the 50 ns MD simulation.
In the systems without the ligand only minor PDZ shifts relative to PD are observed, but the
interface does not open. Further activation-associated events, e.g. PDZ-L3 positional swap
seen in any active HtrA protein (vs. HtrA2), were not observed. In summary, this study pro-
vides hints on the mechanism of activation of wtHtrA2, the dynamics of the inactive
HtrA2V325D, but does not allow to explain an increased activity of HtrA2V226K.
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Introduction
The human HtrA2 (high-temperature requirement A2) protease controls protein quality in
mitochondria [1, 2]. It is involved in cell death (apoptosis, both caspase dependent and inde-
pendent [3–5]) and consequently plays a role in oncogenesis [5, 6]), and in Parkinson [4, 7, 8]
and Alzheimer diseases [9–13]. These properties allow to consider HtrA2 as a potential drug
target in cancer [5, 14] and/or neurodegenerative disorders [4].
The HtrA proteases can be distinguished from other serine proteases by the presence of one
or two C-terminal PDZ (Postsynaptic density of 95 kDa, Disk large, Zonula occludens 1)
domain(s). The protease domain (PD) of the chymotrypsin type consists of two perpendicularly
arranged β-barrel lobes β1-β6 and β7-β12. The lobes are delimited by the N- and C-terminal α-
helices, arranged parallel in space, in a C2-pseudosymmetrical manner. These secondary-struc-
ture elements are connected by loops, several of which are important for proteolytic activity
[15]. The loops are named according to the chymotrypsin nomenclature: LA(β1-β2), LB(β3-
β4), LC(β5-β6), LE(β4-β5) in the N-terminal barrel and LD(β7-β8), L1(β9-β10), L2(β11-β12),
L3(β8-β9) in the C-terminal one [16] (Fig 1). The active site and the catalytic triad (His, Asp,
Ser) are embedded in the interface of the β-barrels.
The PDZ domains participate in the regulation of HtrA activity by recognizing and binding
hydrophobic C-terminal sequences of substrates or regulatory peptides. The HtrA monomers
form higher-order oligomers. The common structural unit is a pyramid-shaped trimer with
PDs constituting the pyramid walls and their N-termini adding to a central core around the
pyramid apex, while the PDZ domains protruding outward laterally at the pyramid base. Two
bacterial HtrAs, the E. coliDegP and DegQ proteases, which contain two PDZ domains, further
oligomerize forming up to 24-mers. Regardless the oligomerization status, at low temperatures
or in the absence of a substrate or activating peptides HtrAs adopt inactive conformations
characterized by non-catalytic architecture of the triad and/or a restricted access to the active
site. Hence, it is generally accepted that HtrA proteases are activated [15, 17–20] by binding of
a specific activator at the PDZ domain and a substrate at the active site.
HtrAs share ~60% sequence homology. A number of crystal structures of pro- and eukary-
otic HtrAs have been solved to date [17, 20–34], demonstrating that the enzymes exist in at
least two distinct conformations: resting and active states. There are several recent reviews on
structure-function relationships within HtrAs [15, 19, 35], including a minireview in the intro-
duction to our previous work [36].
Human HtrA2 has a single PDZ domain and in the crystal structure forms a pyramid-
shaped homotrimer. The catalytic triad located in an interior (concave) of the trimer—a feature
shared by the whole HtrA proteins family—comprises H198, D228, and S306 (S306A mutation
in the crystal [31]) in a noncanonical, catalytically inactive orientation [19]. PDZ and PD are
connected by a flexible linker. PDZ contains a typical peptide binding groove between β14 and
α7 starting from a peptide-recognition motif 361YIGV364, the PDZ-specific carboxylate-bind-
ing loop β13-β14 [37]. In HtrA2 the groove is buried in the tight interface between PDZ and
PD, and so is the PD active site; this being a unique structural feature of this protein, not
observed in other family members, letting the trimer compare to a budding flower or—its
monomer unit—to a lid-enclosed jug. PDZ packs against PD through van der Waals contacts,
involving two clusters of hydrophobic residues in (β11-L2-β12)PD-(β14-α5)PDZ (hereafter
hinge A) and (β5-LC-β6)PD-(β13/α7)PDZ (hinge B). With PDZ taken as a lid to PD, the hinges
are located at the C- and N-barrels within the PD domain, respectively [31]. According to Li
et al. [31], HtrA2 activation requires an activating peptide to bind at hydrophobic groove of
PDZ, which leads to the opening of the PDZ-PD interface and enables protease activity. The
model is supported by the fact that PDZ-deleted HtrA2 variant is more active than the full-
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length protein [31, 38]. Moreover, specific peptides binding to the PDZ domain increase the
HtrA2 activity [9, 39]. HtrA2 activity is also up-regulated in response to a heat-shock [40].
Available evidence jointly suggests that activation of HtrA2 may resemble that of DegS [24,
26]. However, while in DegS the PDZ domain only stabilizes the inactive form of the protease,
in HtrA2 it physically blocks the access of the substrate to the active site.
Recently, we have investigated temperature-dependent (20–45°C) conformational changes
in HtrA2 using single-tryptophan mutants at the PD/PDZ interface and monitoring fluores-
cence of this residue. Correlation of temperature dependence of fluorescence and catalytic rates
in selected mutants allowed us to elucidate the role of particular amino acids in regulation of
protease activity [36]. We have concluded that when the HtrA2 structure relaxes and the
PDZ-PD interface opens, the PD part of hinge A retains its structural integrity. As such it does
not tolerate any mutations in the (β11-L2-β12)PD segment, e.g. V325D, without complete loss
Fig 1. Human HtrA2 topology. (A) Protease domain: the N- and C-terminal helices, α1/α2 and α4,
respectively, are omitted for clarity. The catalytic triad His, Asp, Ser and the loops are labeled according to the
chymotrypsin nomenclature [16]. (B) PDZ domain. The carboxylate binding loop is indicated.
doi:10.1371/journal.pone.0161526.g001
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of protease activity. On the contrary, hinge B also retains major interactions upon HtrA2 acti-
vation, but may accommodate favorably selected mutations, e.g. V226K in LCPD, that increase
the proteolytic activity of the protein compared to the wild type HtrA2 [36].
In our most recent study we combined a temperature-dependent tryptophan-induced
quenching (TrIQ) with selected mutation-activity analyses. TrIQ is a modern technique com-
plementary to FRET and efficient at smaller distances (10Å) than the latter [41]. We found
that in activation, PDZ changed its position versus PD of own and of the adjacent subunit PD
(the asterisk indicates the adjacent subunit). These changes included (β14-α5)PDZ slightly clos-
ing distance to “own” LC and L2 and to LD [38] while simultaneously increasing distances
between all other not contributing to the “hinges” (see above) parts of bulk PDZ and PD,
including in particular the regulatory L3 [35, 38] moving away of own PDZ, compare Fig 1 in
[38]. Simultaneously, expanding our former structure-activity mutation study [36], we have
found that any mutations weakening inter-domain interactions at the PD-PDZ-PD interfaces
increase HtrA2 proteolytic activity, see e.g. Figs 3 and 4 and Table 2 in Ref. [38], including the
V226K mutation, see above.
The aim of this study was to examine in details likely routes of HtrA2 activation, compatible
with the above observations. We used the wild type HtrA2, the inactivating mutant in hinge A
(V325D) and the activating mutant in hinge B (V226K) as models. Our successful crystalliza-
tion and structure solution of HtrA2S306A/V226K (having the catalytic Ser routinely disabled to
avoid self-degradation) revealed that S306/A/V226K mutant has the same (inactive) architec-
ture, earlier found for HtrA2S306A [31]. Subsequent molecular dynamics (MD), both unre-
strained and restrained (RMD), have led us to a hypothesis on basic structural requisites to
HtrA2 activation, pertinent to the structure relation between: 1) On the one hand, a unique
tight PDZ-PD interface in the inactive HtrA2 (see above) that confines the regulatory L3 to a
flap on a convex side of the trimer; and 2) On the other, our observation that an active form
turns up to be common for the HtrA family [17, 20, 23, 24, 26, 28–30, 32], featured by opened
PD-PDZ interface, having L3 slid between L2PD and α7PDZ onto the concave side of the trimer,
thus destroying hinge A. Consequently, bringing inactive HtrA2 to this “canonical active archi-
tecture” would require an extensive rearrangement of L3, equivalent with a crack of hinge A
and replacement it with a new (L2-L3)PD- (β13-α7)PDZ interactions, with simultaneous whole
opening of the PD-PDZ interface. An alternative would mean an entirely different activated
HtrA2 architecture than one typical of all active HtrAs resolved thus far.
Methods
Preparation of HtrA2V226K/S306A protein
E. coli strain BL21(DE3) (Novagen, San Diego, USA) transformed with the pET-derived pDZ5
V226K plasmid [36], carrying HtrA2V226K/S306A gene was used to overproduce mutant protein
(amino acids 134–458) with His6-tag at the C-terminal end. The protein was purified by affin-
ity chromatography on Ni-NTA according to the manufacturers' instructions (Qiagen, Wro-
claw, Poland). The concentration of HtrA2V226K/S306A was estimated using Amido Black as
described before [42]. The purity of the HtrA2V226K/S306A preparation was estimated at more
than 95% by SDS-polyacrylamide gel electrophoresis.
Crystallization, data collection and structure solution
Immediately prior to crystallization screening the buffer was exchanged to 5 mM Tris-HCl pH
8.0 containing 150 mMNaCl and 200 mM imidazole by gel filtration on Superdex s75 (GE
Healthcare), the protein was concentrated to 18 mg/ml and screening was performed using sit-
ting drop vapor-diffusion method. Crystals appeared after several days at room temperature in
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Crystal Screen 2 formulation 21 (Hampton Research). The initial conditions were optimized.
The crystals used for measurements were obtained from 0,15 MMES pH 6.5 containing 2 M
NaCl, 0,13 mM KH2PO4 and 0,1 M NaH2PO4. The crystals were cryoprotected in 25% glycerol
in mother liquor and cooled in liquid nitrogen. The diffraction data were collected using in
house rotating anode copper source (MicroMax-007 HF; Rigaku). Data were indexed and inte-
grated with MOSFLM [43]. The following steps were performed using software collected in the
CCP4 package [44]. Data were scaled with Scala [45, 46]. Molecular replacement was per-
formed using Phaser [47] with alanine search model based on the structure of HtrA2 (PDB ID:
1LCY). Model building was performed manually using Coot [48]. Water molecules were added
using Coot and were inspected manually. Restrained refinement was performed with Refmac5
[49]. Throughout the refinement 5% of reflections were used for cross-validation analysis [50]
and the behavior of Rfree was utilized to monitor the refinement strategy. The data collection
and refinement statistics are presented in Table 1. The structure was deposited in PDB with the
accession code 5FHT.
Molecular dynamics of the trimers of HtrA2 and its mutants
As differences between the first HtrA2S306A [31] and the current HtrA2S306A/V226K structure
(5FHT, this work vide infra) have turned out to be negligible, the crystal structure of the former
(HtrA2S306A, pdb code 1LCY [31]) was used as a template. 1LCY and 5FHT have 3 unresolved
Table 1. Data collection and refinement statistics.
PDB ID 5FHT
Wavelength (Å) 1.54
Resolution range (Å) 14.57–1.95 (2.019–1.95)a
Space group H3
Unit cell 86.01 86.01 126.70; 90.0 90.0 120.0
Total reflections 121190 (16150)
Unique reflections 25396 (3720)
Multiplicity 4.8 (4.3)
Completeness (%) 99.6 (99.5)











Ramachandran favored (%) 97.9




aValues in parentheses represent the highest-resolution shell.
doi:10.1371/journal.pone.0161526.t001
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regions, viz: the N-terminal IAP-binding motif 134AVPSP138 and 134AVPSPPPA141;
L3β8~β9
282ARDLGLPQT290 and 281PARDLG286; and the PD~PDZ linker 344RGEKKNSSS-
GISGSQ358 and 345GEKKNSSSGISGSQ358, respectively. We ignored the IAP-binding sequence
as one of no importance in protease function [31], while L3 and the PD~PDZ linker structures
were restored using the BIOPOLYMER and LOOP SEARCHmodules in the SYBYL software
[51]. The obtained model was optimized using the minimization protocol implemented in the
AMBER11 package [52, 53]. PDZ domain in complex with a selectively-binding peptide was
modeled using the crystal structure of the lone (i.e. lacking PD) PDZ-GWTMFWV complex
(pdb code 2PZD) [54] because the PDZ domains in 1LCY and 2PZD overlapped perfectly
(RMS<0.1Å). Several minimizations and short low-temperature MD simulations were per-
formed in repetitive cycles to reduce all steric clash between the introduced peptide and PD
and to simultaneously preserve the initial structure as much as possible.
Based on the above modeled structure the V226K and V325D mutants were constructed.
Additionally their equivalents with the catalytic triad serine replaced by alanine were also built:
S306A, V226K/S306A and V325D/S306A. Each of the latter three was modelled with and with-
out the selective ligand GWTMFWV. All these models were optimized as described above.
Homotrimers compatible with 1LCY crystal structure were made from optimized starting
monomers by imposing the C3 symmetry typical of the 1LCY crystal. Nine constructed starting
homotrimers were separately immersed in a rectangular TIP3P [55] water box of 125x125x95
Å3 size. To neutralize the negative charge on the protein system, 6, 9 and 12 Na+ ions were
added to HtrA2V226K, HtrA2 and HtrA2V325D trimers (and to the matching S306A mutants),
respectively. Each trimer was initially optimized using similar methodology as described for
the monomers.
MD simulations for each of the 9 systems were carried out using the following parameters: 1
fs time step, constant pressure (1 atm) and periodic boundary conditions. SHAKE algorithm
[56] was used for treatment of hydrogen atoms. Long-range electrostatic interactions were sim-
ulated using the Particle Mesh Ewald (PME) method [57] with the cutoff equal to 8Å. Non-
bonding interactions were updated every 25 steps. The simulation temperature was set to 313K
because it is known that the thermally induced activation of HtrA2 is efficient at this tempera-
ture [36, 38]. Each of the simulated systems consisted of about 43,000 water molecules, 3x320
or 3x327 amino acid residues (apo and ligand containing models, respectively), ~145.000
atoms in total. The productive runs were 50 ns long, with snapshots taken every 1 ps. To obtain
the results in a reasonable time, all molecular systems were simulated using AMBER PMED
v2.2 software [58, 59] and NVIDIA GPU-CUDA [60] card hardware.
Restrained (steered) molecular dynamics of the HtrA2 monomer
To this aim, the crystal structure of HtrA2S306A (1LCY [31]) monomer was used as a template.
The L3 (282ARDLGLPQT290) and the linker (344RGEKKNSSSGISGSQ358) gaps in the sequence
were preserved. Moreover, by trial-and-error we found crucial to truncate both the β8 inlet to and
the β9 outlet from the L3 gap, each by extra 8 residues, 274IVSSAQRP281 and 291NVEYIQTD298,
respectively. Otherwise both trunks would sterically hinder optimization of the 1LCY-like start
structure to a target meeting the restraints deduced from TrIQ and having a more open PD-PDZ
interface (see below). All above conditions held, an alternative start, compatible with the
completely open (no PD-PDZ1 interface) structure of the active DegP (PDB file 3CS0) [17] was
used as a control. Nine PD-PDZ distance restraints were imposed in agreement with Fig 1B,C
and Table S3 in Ref. [38]. As TrIQ results provided only tendencies (increase/decrease/keeping of
a Cα-Cα distance) in HtrA2 thermal activation [38, 41], we affixed to these tendencies, specific,
though arbitrarily guessed restraint distances, see Table 2. The harmonic restraints were very soft,
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with force constants equal to 1 kcal/Å. To maintain the complete shape integrities within the PD
and PDZ domains, the backbone angles (φ,ψ,ω) were fixed. Successful restrained MD was carried
out at 45K using AMBER11 [52, 53].
Results
Crystal structure of HtrA2V226K/S306A
To analyze the structural consequences of activating mutation V226K in hinge B of HtrA2 we
obtained a crystal structure of the mutant HtrA2V226K/S306A. Its overall architecture resembles
that of HtrA2S306A [31]. No structural rearrangement of PDZ domains vs. PD domains is
noted compared to HtrA2S306A (RMS<0.4Å, based on 290 [98%] common Cα atoms). Minor
changes are observed only around the mutated residue and on L3. The mutated K226 forms a
hydrogen bond with E425, absent in the HtrA2S306A, while on L3 the unresolved gap reduces
from 9 in HtrA2S306A [31] to only 6 residues 281RARDLG286, more firmly manifesting L3 to
flap on a convex side of the trimer than in 1LCY. The additional hydrogen bond K226-E225
further stabilizes the interaction between PDZ and PD domains in hinge B region (Fig 2). Pre-
vious studies have demonstrated that the HtrA2E425L exhibits activity comparable to
HtrA2V226K and the activities of both mutants are higher compared to that of the wild type
Table 2. The restraints used in restrained MD of 1LCYmonomer. The values in the middle column are inferences affixed to tendencies given in Fig 1 B,
C in Ref. [38].
Distance, [Å]
Cα- Cα 1LCY [31] Restraint Optimized, see Results
I179- L398 7.96 26.00 23.5
A201-Y361 8.44 13.00 14.6
P225-Y361 8.47 13.00 13.0
P225-V364 8.79 13.00 13.6
M323-P384 17.19 25.00 21.2
M323-M365 8.93 9.00 10.7
F331-M365 12.31 12.00 12.1
V226-L367 9.71 8.00 9.5
F331-I373 11.13 10.00 12.0
doi:10.1371/journal.pone.0161526.t002
Fig 2. Interdomain interactions in hinge B area. Left: HtrAS306A (1LCY) [31] andRight:HtrAV226K/S306A
(5FHT; this work). Proteolytic domain is colored magenta, PDZ domain—blue. In the V226K mutant (Right)
the distance 2,8Å indicates an H-bond/ionic pair Lys226(LC)PD -E425(α7)PDZ, absent in HtrA2 (Left).
Otherwise, both structures overlap perfectly on each other, see text.
doi:10.1371/journal.pone.0161526.g002
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[36]. While V226K mutation creates an additional hydrogen bond adding to the PD-PDZ
interaction, the E425L mutation results in hydrophobic interaction of V226 and L425 within
the same region of the protein, with a like effect in the inactive structure of HtrA2(Omi).
Preliminaries of molecular dynamics
Since the gaps in L3 and the PD-PDZ linker, not defined in the crystal structure, were restored
computationally (see Materials and Methods), all the models were subject to initial optimiza-
tion to relax any unfavorable contacts. This optimization only minutely adjusted the PD-PDZ
arrangement compared to that seen in the crystal structure (Fig 3). This is evidenced by small
values of root-mean-square (RMS) deviation calculated for the positions of Cα atoms between
the optimized trimers and those found within the crystal structure of HtrA2S306A (1LCY) [31]
(Table 3). The most pronounced adjustments concerned: i) unresolved fragments added com-
putationally, including the ligand, and ii) adjustments of monomers at their interfaces within
the trimer. None of the adjustment steps exceeded 1 Å of total RMS.
Importantly, the ligand-binding and the apo structures have optimized similarly demon-
strating the correctness of our approach to modeling the peptide in complex with the apo-
HtrA2. The GWTMFWV peptide fits surprisingly well to the apoPD-PDZ interface. Notably,
its insertion into 1LCY has introduced only 2 new contacts (using the 3.5 Å criterion) with PD,
viz. those of W2 with F331(β12) and W6 with A197(LB). Based on the mere geometrical
Fig 3. Optimized starting trimer of HtrA2. Upper panel: The view perpendicular to the C3 axis onto the
concave of the trimer. Units A-C are distinguished by color of protease domain ribbons: blue (A), green (B),
yellow (C); the PDZ domains are shown uniformly as pink ribbons. The restored fragments, missing in 1LCY
structure: L3, PD-PDZ-linker and the ligand, are highlighted as orange threads (plus short orange helices
constituting part of the linkers). Lower Panel Left:Orientation as above, PDs are represented by a gray
surface. PDZ ribbons (making 3 lids to the PDs) and modeled fragments are colored as above. Lower Panel
Right. A lateral view of the latter. Selected features in the units are labeled in all views.
doi:10.1371/journal.pone.0161526.g003
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criterion, they appeared as modest as 7 contacts already present in the crystal structure of
PDZ-ligand, viz. with (M366,L367)β14, E376α5, (H394,I397)β15 and (A424,Y428)α7 [54]. A
minor adjustments of W2-T3 in the ligand and of β11-L2-β12 in PD have alleviated these unfa-
vorable interactions. Thus, the ligand pocket of PDZ, even if seemingly inaccessible in resting
HtrA2, is spacious enough to accept the heptapeptide.
Productive molecular dynamics
Within 50 ns MD simulations each system experienced mainly specific segmental/collective
motions of PDZ and PD domains relative to each other (Table 4), but retained intra-segmental
consistency within the domains. Save for the N-terminal α1 (residues 139–150), β1-LA-β2 (res-
idues 168–177), L3 (residues 282–290) and the PD-PDZ linker (residues 346–352), which have
undergone more pronounced rearrangements, inherent drifts of the domains from their origi-
nal architectures have not been larger (RMS) than 1.2–1.5Å and 1.1–1.3Å for ~100 PDZ and
~160 selected PD Cα atoms, respectively. It is important to note that two of the four most
dynamic structure elements, L3 (9 residues) and PD-PDZ-linker (15 residues) were those
restored algorithmically [51]. Therefore they might have had their starting 3D architectures
not soundly consistent with the structural context of the reported HtrA2 trimer and as such
expectedly could have exhibited increased mobility to adjust to surrounding structure
Table 3. Modeling statistics of the starting structures.
RMS [Ǻ]: steps i) and ii); (step i) only) [see text] HtrA2S306A b HtrA2S306A-pepc
1LCY [31] a 1.7; (0.8) 1.8; (1.0)
HtrA2S306A b 1.0; (0.9)
a 1LCY: Cα-based RMS calculation excludes residues unresolved in 1LCY [31] structure.
b HtrA2S306A exemplifies 3 tested mutants: S306A, S306A/V226K and S306A/V325D, whose optimized
starting structures fit to RMS<0.1 Ǻ.
c HtrA2S306A-pep exemplifies 6 tested cases containing peptide ligand: S306A, S306A/V226K, S306A/
V325D, HtrA2 wild-type, V226K and V325D, whose optimized starting structures fit mutually to RMS<0.1 Ǻ.
doi:10.1371/journal.pone.0161526.t003
Table 4. Overview of simulation results. For a viewer having the N-terminus and PD C-terminal barrel in
the foreground, as in Fig 5, “cc” and “c” denote, respectively, counterclockwise and clockwise rotation of PDZ
versus PD. The viewer sees this rotation roughly round an axis parallel to α4 and passing for “cc” between α4
and α7, see Fig 5, and; for “c” by the peptide-binding motif 361YIGV364. “Δ”applies to “cc” only and refers to
another measure of extent of the “cc” rotation, viz. to its associated arc at maximized radius. I179(β2) and
L398(β15) roughly fit this radius tips, hence their Cα-Cα (vs. ~6Ǻ at the start) distance increases with “cc” rota-
tion defining “Δ“. “i” indicates minute irregular motions.
Unit A Unit B Unit C (Refer to Fig 5)
containing peptide ligand
HtrA2 cc ~30°/ Δ = 16.4 Ǻ cc ~0°/Δ = 10.5 Ǻ cc ~40°/Δ = 23.1Ǻ
HtrA2S306A i cc ~50°/Δ = 24.4 Ǻ i
HtrA2V226K c ~10° i i
HtrA2V226K/S306A i i i
HtrA2V325D i i i
HtrA2V325D/S306A i i i
no ligand (apo)
HtrA2S306A i i i
HtrA2V226K/S306A i i i
HtrA2V325D/S306A i i i
doi:10.1371/journal.pone.0161526.t004
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environments. Therefore, the only significant motions observed in the simulations have
included segmental translations/rotations of PDZ relative to PD within each monomer (Figs 4
and 5).
The segmental motions observed in the simulated models classify into three basic types
(Table 4). The prevailing motion relies on minor and apparently non-specific rearrangements
of PDZ versus PD. It is seen in all but one monomers of the HtrA2S306A and HtrA2V226K mod-
els, all monomers of HtrA2V226K/S306A, HtrA2V325D, HtrA2V325D/S306A models in the peptide
containing trimers, as well as in the all apo HtrA2S306A, HtrA2V226K/S306A and HtrA2V325D/S306A
trimers.
Wild type ligand-bound HtrA2 and HtrA2S306A exhibit the second type of motion. With the
MD progress two monomers within the former structure and one within the latter have per-
formed a relatively consistent motion, illustrated in Fig 5. For a viewer having the N-terminus
and the C-terminal barrel of PD in the foreground, PDZ rotates counterclockwise relative to
PD around an axis between and roughly parallel to α4PD and α7PDZ, simultaneously passing
near the N-front of α5PDZ. Some translation, hard to characterize with math rigor (see, how-
ever, Supplementary Material, containing the Principal Component Analysis, PCA, of the
MD results), accompany the rotations of these units. The rotations are equivalent to opening
the PD-PDZ interface in a lid-like way. The two hinges (A and B) are made of clusters of
hydrophobic residues. The rotation of up to 50° (Table 4 and Fig 5) enables complete access
both to the catalytic triad in PD and the peptide-binding site in PDZ. It is surprising that a sim-
ilar motion is not seen in MD of HtrA2V226K, even though this mutant was demonstrated
experimentally to exhibit increased proteolytic activity compared to the wild type [36].
The last type of motion, seen only in a single monomer of the ligand-bound HtrA2V226K
also lifts the lid, but only slightly, about 10°, clockwise and “another way around”, as if the
hinges were now fixed on the opposite side of the PD-PDZ interface. Trajectory analyses using
the math rigors of PCA (see Supplementary Material) have confirmed the above conclusions.
Our results demonstrate that the motions within the monomers in the trimer are not syn-
chronous in the timescale of 50 ns (Fig 4). By selecting a pair of residues most remote to the
hinges, e.g. PDZ(lid) L398(β15-α6 loop) with PD(jug) I179(β2) we measured the extent of
opening of the PD-PDZ interface (Table 4 and Fig 5) in diverse units.
Fig 4. HtrA2 trimers after 50 ns MD, with reference to the starting structures: The pink PDZ (ribbons)
make 3 lids to the PD (surface) of the trimer viewed perpendicular to C3 as in Fig 3. Left: The resultant
wtHtrA2-ligand complex. PDZ domains, in Units A, B, C, (cyan, canary and amber ribbons, respectively)
have moved equatorially (budding-flower-like) relative to their starting (pink) positons, especially in units A &
C thus opening the PD-PDZ interface.Right: The resultantHtrA2S306A/V325D double mutant-ligand
complex. Moving PDZ domains are colored as in the left panel. Only minor PDZ motions are seen; no
opening of the PD-PDZ takes place.
doi:10.1371/journal.pone.0161526.g004
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The conformations of the catalytic triad residues were analyzed in the optimized starting and
resultant product structures and have been found catalytically incompetent, as seen previously
in the crystal structure. Typical distances in a catalytically ready triad in serine proteases of the
HtrA type amount to 3.15±0.2 Ǻ for the Oγ(Ser)-Nε2(His) distance and to 3.3±0.4 Ǻ for the
Nδ1(His)-Oδ1(Asp) distance ([19], compare also Ref. [32]). The average lengths of the sides of a
triangle formed by the Cα-Cα distances within the catalytically competent triad, ΔS-H = 8,6±0.1
Ǻ, ΔD-H = 6.5±0.1 Ǻ and ΔS-D = 10.2±0.1 Ǻ) alike serve as a criterion of the catalytic competence
of HtrA2. Neither any starting nor resultant structures have fitted these criteria. We speculate
that substrate binding induces further rearrangements yielding a proteolytically competent con-
formation within the catalytic triad, though this is not reflected in our simulations where sub-
strate has not been taken into account.
Restrained Molecular Dynamics (RMD)
In Figs 5 and 6 of our recent work [38] we have sketched an initial step to thermal activation of
HtrA2, complying qualitatively with the TrIQ restraints. The model relies on a slight opening
of the PD-PDZ(red) interface, in agreement with the MD results given here in Figs 4 and 5. In
Fig 5. HtrA2-ligand complex unit C after 50 ns MDwith reference to the initial structure.All but the top-
right views have common orientation. PD N-terminal α1-α2 and C-terminal barrel are in the foreground (bottom,
dark blue ribbon), while C-terminal α4 and N-terminal barrel are in the background (bottom, light blue ribbon).
α1-α2 and α4 axes run roughly perpendicular to the figure plane. Important features of the structure and its
dynamics are indicated. Top-left: Unit C as extracted from the trimer in Fig 4 left panel, and reoriented (see
above).Bottom-left: As above, PD unwrapped form the surface. Top-right: Unit C is rotated 90° round the
vertical axis to show relationships between the PDZmotion and exposure of the catalytic triad (olive green).
Bottom-right: Visualization of a true uncovering of the catalytic triad after ca. 40° PDZ counterclockwise
rotation (lid-opening) during the 50 ns MD, characterized in detail in the neighbor bottom-left panel and in
Table 4.
doi:10.1371/journal.pone.0161526.g005
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order to more rigorously resolve the PD-PDZ orientation fulfilling these restraints [38], now
we have worked out the TrIQ results using RMD and arrived at the following results (see also
Table 2). (i) Satisfying the TrIQ-inferred temperature-driven increases and decreases of
selected 9 intra-unit distances is unfeasible, unless the already incomplete L3 is further
Fig 6. HtrA trimers; PD-PDZ(1) in surface representation. L3 and the linker are shown as orange threads,
L2, L1 and LD as blue threads. (A) wtHtrA2-peptide starting structure in orientation identical to that in Fig 3
bottom-right. (B) wtHtrA2-peptide after 50 ns MD. (C) active DegP PDB (entry 3CS0 [17]) PDZ2 is omitted for
clarity. In contrast to A andB, where L3 protrudes outside on the convex side of the trimer, in the active DegP
and in other active HtrAs (not shown) L3 enters between PD and PDZ, onto the trimer’s concave, contributing
(vide bottom) to the allosteric activation cascade: L3*-LD-L1-L2 [35].
doi:10.1371/journal.pone.0161526.g006
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truncated at each the β8 inlet to, and the β9 outlet from the L3 gap by extra ~8 residues, which
removes steric hindrance of L3 to optimization. (ii) The optimization arrives at the same result
no matter starting PD-PDZ orientation, i.g. the fully closed 1LCY-like [31] or fully open
3CS0-like, see Methods. (iii) The result, defined by the nine Cα-Cα distances given in the last
column of Table 2, features a PD-PDZ opening intermediate between that in Fig 5 this work
and Figs 5 and 6 in [38].
Discussion
The crystal structures of HtrA2S306A [31] and HtrA2S306A/V226K (this work) resolve to homotri-
mers having essentially identical architectures, characterized by a unique PD-PDZ arrange-
ments not seen in the structures of other procaryotic and eukaryotic proteins of HtrA family.
In contrast to the other family members, regardless in proteolytically more or less active forms,
the catalytic and the PDZ domains in HtrA2 tightly pack against each other [31]. A major con-
sequence of this feature is an apparent inaccessibility of the activating-peptide binding site on
the PDZ part and of the substrate pocket on the PD part in both structures. As such, the struc-
tures meet a model of an inactive HtrA2(Omi) protein [31].
In our 50 ns MD simulation, two subunits in the trimers of HtrA2-ligand and one in the tri-
mer of HtrA2S306A-ligand (Figs 4 and 5 and S1, S2 and S4 Figs) have reorganized in agreement
with an opening of the tight PD-PDZ interface by lid-like rotations of ~30°-50° (Fig 5 and
Table 4). The rotation was around an axis ~parallel to and located between α4PD and α7PDZ
and passing by hinges A and B (Figs 4 and 5 and S4 Fig). These rotations resemble opening of
the inactive HtrA2 toward structures typical of all proteolytically-competent HtrAs determined
to date. The motions are in agreement with the FRET result reported by Chaganti et al. [61]
because, while releasing access to the PDZ and PD binding sites, they maintain the F341Cα4-
Y428Wα7 (F208Cα4-Y296Wα7 in their terminology) distance in hinge B roughly intact, as con-
cluded from their FRET measurements [61]. These Authors also studied HtrA2 allosteric acti-
vation using MD [61–63]. They stipulated that the inactive, closed form of HtrA2 employs a
non-canonical binding groove by the PD-PDZ interface, before being able to utilize the canoni-
cal peptide-recognition motif [62] i.e. the (β13-β14)PDZ carboxylate-binding loop, see above. In
this work we neither pursue this issue nor the allosteric regulation of HtrA2 (caspase-depen-
dent) via its N-terminus [63].
To date, 15 proteolytically active HtrA structures of widely diverse origin have been pub-
lished, including E. coliHtrA(DegP) [17],Mycobacterium tuberculosisHtrA2 [23], E. coli DegS
[20, 24, 26, 32], Legionella falloni DegQ [28], plant Arabidopsis thaliana Deg1 [29] and human
HtrA1 [30]. We note that their common feature is a similar mutual location (even if diverse
orientation) in space of their PDZ (PDZ1 in DegP and DegQ [17, 28]) vs. PD domains. Both
domains do not form an interface. In the human HtrA1 the PDZ domain is not resolved within
the crystal structure due to its high flexibility [30], however, HtrA1 can be active without PDZ
domain. Similarly, human HtrA3 [34] and E. coli DegS [20, 26, 32] do not require PDZ domain
for activity. Even more conservative, shared by all structures of the active proteases are the
positions of the sensor loop L3. Despite its length varying by up to 6 residues between different
HtrA proteases, L3 occupies in all active HtrA proteases a specific site between PD and PDZ
domains, where it separates L2PD and α7PDZ(1), simultaneously being in contact with LD of
the proximal unit of the trimer (asterisk denotes a neighboring monomer). In fact, these com-
monalities apply to all three L3-LD-L1-L2 “activation clusters” per trimer, mutually related by
the C3-symmetry (Fig 6C) [15, 19, 35]. On the contrary, in the structure of inactive human
HtrA2 and during entire MD simulation carried out for HtrA2- and HtrA2S306A-ligand system
the sensor loop L3 persists in clearly different site.
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Fig 6 illustrates that L3 and (β13-α7)PDZ (proximal to the C-barrel side of PD, a part of
hinge A) are in HtrA2 (Fig 6A) reversely positioned in space than they are in an active structure
of any HtrA protein, taken DegP as an example (Fig 6C). Moreover, this “wrong” arrangement
augments with the progress of MD (Fig 6B). None of the subunits exhibiting the PD-PDZ
opening motion is capable of letting L3 enter between the own C-barrel and PZD as required
to activate the protease. Reversely, the opening motion(s) pushes L3 more equatorial, to the
exterior (convex) side of the gradually opening concave of the PD-PDZ interface (Fig 6A and
6B). In a view of the published experimental data on specific contribution of L3 in the activa-
tion process, it is clear that the (semi)open HtrA2 units do not approach true active states in
MD. To achieve this, L3 and PDZ should have swapped their positions (Fig 6C), a too demand-
ing task for any simple MD. This structural requisite is diagrammatically presented in Fig 7 for
a monomeric unit.
It is noteworthy that the HtrA2V226K/S306A mutant (Table 1, entry 5FHT), crystallizing ver-
sion of HtrA2V226K more active than the wtHtrA2 [36], has crystallized in exactly the same
inactive architecture as HtrA2S306A [31], with its L3 even more distinctly flapped out to the
exterior (convex side) of the PD-PDZ interface than the latter.
In summary, X-ray study combined with MD failed to explain higher proteolytic activity of
the V226K mutant, because in the MD simulations wtHtrA2-ligand complex exhibits more
pronounced PD-PDZ opening than HtrA2V226K-ligand does, while one would expect the
opposite from comparing their activities. At the same time our studies explain the inactive phe-
notype of V325D mutant, which manifests no tendency to PD-PDZ opening in the MD simu-
lation. Our results, combined with accumulated knowledge about structures of activated HtrAs
has led to structural requirements, drawn schematically in Fig 7, that have to be met on a path
from inactive to proteolytically active HtrA2(Omi) protease. While opening the PD-PDZ inter-
face, somewhere on a way to activation an L3-PDZ positional swap is required, which could
only be attained upon a crack of hinge A, the (β11-L2-β12)PD-(β14-α5)PDZ cluster, while
retaining hinge B, the (β5-LC-β6)PD-(β13-α7)PDZ cluster still conserved. Clearly, the exact
structural changes involved in the activation mechanism of HtrA2 remain open to debate until
the crystal structure in the proteolytically active form is solved.
Fig 7. Diagrammatical scheme of structural requisite to HtrA2 proteolytic activation. N-helix and barrel are colored blue,
C-barrel and helix are cyan, L3 is green, the triad is red, PDZ domain is pale yellow orthorhombic box. Left: Inactive closed
form, L3 flaps on the exterior (convex in the trimer) side, opposite the location of the triad.Right: Active open form, L3 is slid
between C-barrel and PDZ to the interior (concave in the trimer) side, disrupting hinge A.
doi:10.1371/journal.pone.0161526.g007
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Supporting Information
S1 Fig. PCA of wtHtrA2/peptide trimer. Three most significant eigenvectors, modes 1–3, are
represented as square displacements of sequential MD-time-averaged Cα coordinates. The sec-
ondary-structure elements of HtrA2 monomer (1LCY pdb entry) are indicated below the
abscissa for reference. Clearly, the majority of segmental motions are explained in mode 1, as
modes 2 and 3 contain only residual fluctuations of LB, L3 and the PD-PDZ linker. Unit A is in
red, unit B green, unit C blue. The lower-bottom panel includes respective scree plots.
(PDF)
S2 Fig. PCA of HtrA2S306A/peptide trimer. General legend see S1 Fig. Majority of segmental
motions are explained in the first two modes, as mode 3 contains only residual fluctuations of
LB, L3 and the PD-PDZ linker.
(PDF)
S3 Fig. PCA of apo HtrA2S306A trimer. General legend see S1 Fig. Majority of segmental
motions are explained in the first two modes, as mode 3 contains only residual fluctuations of
LB, L3 and the PD-PDZ linker.
(PDF)
S4 Fig. Visualization of motional modes 1–3 within unit C of wtHtrA2-peptide complex.
Directional amplitudes (double-arrow modules ~ root squares of displacements in S1 Fig). of
PCA-factorized motional modes of wtHtrA2-peptide complex are depicted on the HtrA2
mean structure. Cα-trace was interpolated to a smooth curve using VMD. The structures, in
stereo, are oriented in agreement with all but top-right structures in Fig 5. Selected secondary-
structure elements in mode 2 are marked. The motional arrows are not to the scale of decreas-
ing variance (λ1/λ2/λ3 = 0.58/0.08/0.06). Instead, they are progressively scaled up by 0.87•(λ1-
1/2, λ2-1/2, λ3-1/2), to visualize motions in modes 2 and 3. Double-arrows are cut off below
2Å, to expose only distinct segmental motions in each mode.
(PDF)
S1 File. Supporting methods and results.
(PDF)
S1 Table. PCA of wtHtrA2/peptide trimer: the summary of the first 30 PCAmodes. Factors
3 to 30 accumulate 48% to 85%, respectively, of total variance in Unit B, fair scree; and 73% to
93%, respectively, of total variance in Unit C, steep scree.
(PDF)
S2 Table. PCA of HtrA2S306A/peptide trimer: the summary of the first 30 PCAmodes.
Factors 3 to 30 accumulate 67% to 91%, respectively, of total variance in Unit A, fair scree; and
81% to 96%, respectively, of total variance in Unit B, steep scree.
(PDF)
S3 Table. PCA of apo HtrA2S306A trimer: the summary of the first 30 PCA modes. Factors
3 to 30 accumulate 49% to 88%, respectively, of total variance in Unit C, fair scree; and 69% to
91%, respectively, of total variance in Unit A, moderate scree.
(PDF)
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